KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $3.6 billion.

  • Teva Pharmaceutical Industries' Cash & Equivalents rose 775.76% to $3.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $3.6 billion, marking a year-over-year increase of 775.76%. This contributed to the annual value of $3.6 billion for FY2025, which is 775.76% up from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Cash & Equivalents stood at $3.6 billion for Q4 2025, which was up 775.76% from $2.2 billion recorded in Q3 2025.
  • Teva Pharmaceutical Industries' 5-year Cash & Equivalents high stood at $3.6 billion for Q4 2025, and its period low was $1.7 billion during Q1 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' median Cash & Equivalents value was $2.2 billion (recorded in 2022), while the average stood at $2.5 billion.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Cash & Equivalents surged by 4757.67% in 2024, and later plummeted by 4326.31% in 2025.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' Cash & Equivalents stood at $2.2 billion in 2021, then rose by 29.38% to $2.8 billion in 2022, then rose by 15.17% to $3.2 billion in 2023, then rose by 2.29% to $3.3 billion in 2024, then grew by 7.76% to $3.6 billion in 2025.
  • Its last three reported values are $3.6 billion in Q4 2025, $2.2 billion for Q3 2025, and $2.2 billion during Q2 2025.